Bang & Olufsen A/S
19.3.2026 13:20:54 CET | Globenewswire | Press release
MAJOR SHAREHOLDER ANNOUNCEMENT
MAJOR SHAREHOLDER ANNOUNCEMENT
Bang & Olufsen A/S has, pursuant to the Danish Capital Markets Act, received a major shareholder notification from UBS Group AG.
- As per 13 March 2026, UBS Group AG’s holding of shares and voting rights pursuant to section 38 of the Danish Capital Markets Act, as well as other financial instruments pursuant to section 39(2), was below 5 percent of the total share capital and voting rights in Bang & Olufsen A/S.
As of 13 March 2026, UBS Group AG held a total of 7,363,317 shares and voting rights in Bang & Olufsen A/S, corresponding to 4.998 percent of the total share capital and voting rights.
For further information, please contact:
Cristina Rønde Hefting
Sr. Director, Head of Strategy & Investor Relations
Phone: +45 4153 7303
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Schneider Electric19.4.2026 09:00:00 CEST | Press release
Challenge accepted: Schneider Electric helps industry turn toughest problems into competitive advantage
Chery Group18.4.2026 15:54:00 CEST | Press release
iCAUR V27 Secures CATARC L3 Off-Road Certification, Solidifying Its New Energy Off-Road Capability with Robust Technology
Sanofi Winthrop Industrie18.4.2026 12:00:00 CEST | Press release
Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study
Organizing Committee of the 2026 Fujian Provincial Conference on the Development of Cultural and Tourism Economy18.4.2026 06:50:27 CEST | Press release
2026 Fujian Provincial Conference on Development of Cultural, Tourism Economy opens on Apr. 17 in Zhangzhou, SE China's Fujian
Evaxion17.4.2026 21:10:00 CEST | Press release
Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom